CCL20 and multiple sclerosis: Li et al. [23] showed that the serum SIRT1 level was decreased and the level of inflammatory chemokine CCL20 was increased in patients with multiple sclerosis, suggesting that SIRT1 may inhibit the expression of CCL20 through the NF-κB pathway, and the lack of SIRT1 may be involved in the pathogenesis of multiple sclerosis.